During the past decade, National Hospital Organization Shikoku Cancer Center conducted 60 clinical trials. In the 10-year time frame, 60 clinical trials started and 32 clinical trials were completed, i.e. on average, 53.3% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 24 clinical trials were completed. i.e. 72.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Hospital Organization Shikoku Cancer Center" #1 sponsor was "Pfizer" with 18 trials, followed by "Amgen" with 6 trials sponsored, "Eli Lilly and Company" with 5 trials sponsored, "Gynecologic Oncology Group" with 4 trials sponsored and "National Cancer Institute (NCI)" with 4 trials sponsored. Other sponsors include 39 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Hospital Organization Shikoku Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 7 trials as a collaborator, "AstraZeneca" with 4 trials as a collaborator, "NRG Oncology" with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 3 trials as a collaborator and "Astellas Pharma Inc" with 2 trials as a collaborator. Other collaborators include 32 different institutions and companies that were collaborators in the rest 38 trials.

According to Clinical.Site data, the most researched conditions in "National Hospital Organization Shikoku Cancer Center" are "Ovarian Cancer" (7 trials), "Breast Neoplasms" (5 trials), "Breast Cancer" (4 trials), "Gastric Cancer" (3 trials) and "Non-Small Cell Lung Cancer" (3 trials). Many other conditions were trialed in "National Hospital Organization Shikoku Cancer Center" in a lesser frequency.

Most popular intervention types in "National Hospital Organization Shikoku Cancer Center" are "Drug" (74 trials), "Other" (12 trials), "Radiation" (7 trials), "Biological" (5 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Paclitaxel" (8 trials), "Laboratory Biomarker Analysis" (6 trials), "Carboplatin" (5 trials) and "Docetaxel" (5 trials). Other intervention names were less common.

The vast majority of trials in "National Hospital Organization Shikoku Cancer Center" are 52 trials for "All" genders, 24 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "National Hospital Organization Shikoku Cancer Center". undefined are not yet recruiting, 18 are recruiting, 31 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in National Hospital Organization Shikoku Cancer Center, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in National Hospital Organization Shikoku Cancer Center, 7 "Phase 1" clinical trials were conducted, 24 "Phase 2" clinical trials and 46 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".